Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine plus streptozocin with or without cisplatin for advanced neuroendocrine tumors
ISRCTN35124268Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jun 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial in apudoma (NET), islet cell tumor and Gastroenteropancreatic Carcinoid Tumor comparing Capecitabine + streptozocin with Capecitabine + streptozocin + cisplatin (2 arms). Primary endpoint: Objective response rate. Started Jun 2005; status: completed.
02
Drugs
capecitabinestreptozocincisplatin
03
Conditions
apudoma (NET)islet cell tumorGastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on ISRCTN35124268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN35124268.